Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

Kevin Lee Biography and Net Worth

CEO of Bicycle Therapeutics

Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Kevin studied pharmaceutical sciences at Nottingham University, followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick. In addition to his seat on Bicycle’s board of directors, Kevin is also a non-executive director of NodThera Ltd.

What is Kevin Lee's net worth?: The estimated net worth of Kevin Lee is at least $9.08 million as of April 3rd, 2024. Dr. Lee owns 387,270 shares of Bicycle Therapeutics stock worth more than $9,081,482 as of April 20th. This net worth estimate does not reflect any other investments that Dr. Lee may own. Additionally, Dr. Lee receives an annual salary of $1,310,000.00 as CEO at Bicycle Therapeutics. Learn More about Kevin Lee's net worth.
How old is Kevin Lee?: Dr. Lee is currently 56 years old. There are 5 older executives and no younger executives at Bicycle Therapeutics. Learn More on Kevin Lee's age.
What is Kevin Lee's salary?: As the CEO of Bicycle Therapeutics plc, Dr. Lee earns $1,310,000.00 per year. Learn More on Kevin Lee's salary.
How do I contact Kevin Lee?: The corporate mailing address for Dr. Lee and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Kevin Lee's contact information.
Has Kevin Lee been buying or selling shares of Bicycle Therapeutics?: In the last ninety days, Kevin Lee has sold $75,191.98 in Bicycle Therapeutics stock. Most recently, Kevin Lee sold 3,158 shares of the business's stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a transaction totalling $75,191.98. Following the completion of the sale, the chief executive officer now directly owns 387,270 shares of the company's stock, valued at $9,220,898.70. Learn More on Kevin Lee's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 21,846 shares worth more than $438,909.08. The most recent insider tranaction occured on April, 11th when insider Michael Charles Ferguso Hannay sold 257 shares worth more than $5,779.93. Insiders at Bicycle Therapeutics own 10.2% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 4/11/2024.

Kevin Lee Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2024	Sell	3,158	$23.81	$75,191.98	387,270
1/3/2024	Sell	8,703	$17.50	$152,302.50	390,428
10/3/2023	Sell	1,470	$20.00	$29,400.00	322,131
7/3/2023	Sell	1,498	$25.10	$37,599.80	323,601
4/3/2023	Sell	1,486	$21.11	$31,369.46	325,099
1/3/2023	Sell	6,000	$29.06	$174,360.00	326,585
10/18/2021	Sell	49	$60.00	$2,940.00
10/14/2021	Sell	4,631	$60.00	$277,860.00
10/11/2021	Sell	5,000	$53.88	$269,400.00
8/31/2021	Sell	11,225	$36.33	$407,804.25
8/27/2021	Sell	1,808	$36.02	$65,124.16	246,893
7/26/2021	Sell	100	$36.00	$3,600.00
7/23/2021	Sell	4,782	$36.02	$172,247.64
7/16/2021	Sell	609	$34.00	$20,706.00
7/14/2021	Sell	14,465	$34.34	$496,728.10	256,670
7/12/2021	Sell	1,936	$32.04	$62,029.44
5/6/2021	Sell	1,716	$32.14	$55,152.24	256,450
5/4/2021	Sell	897	$32.03	$28,730.91	258,125
4/30/2021	Sell	58,919	$30.86	$1,818,240.34	277,229
4/28/2021	Sell	22,495	$31.08	$699,144.60	277,229
4/26/2021	Sell	18,611	$31.28	$582,152.08	273,345
1/19/2021	Sell	5,000	$29.26	$146,300.00	260,556
1/15/2021	Sell	10,000	$26.01	$260,100.00	270,085

Kevin Lee Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $23.45

$23.06

$24.61

50 Day Range

MA: $23.80

$17.42

$26.10

2 Week Range

Now: $23.45

$12.54

$28.91

Volume

546,482 shs

Average Volume

382,602 shs

Market Capitalization

$704.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Your Money is Not Safe

From American Alternative | Ad

CLICK HERE TO GET YOUR GUIDE NOW

Kevin Lee Biography and Net Worth

What is Kevin Lee's net worth?

How old is Kevin Lee?

What is Kevin Lee's salary?

How do I contact Kevin Lee?

Has Kevin Lee been buying or selling shares of Bicycle Therapeutics?

Who are Bicycle Therapeutics' active insiders?

Are insiders buying or selling shares of Bicycle Therapeutics?